- A2A and beta-2 adrenergic receptor agonists were shown to be highly synergistic and selective agents providing enhanced glucocorticoid activity in B-cell malignancies.
- Analysis of agonists in combination with dexamethasone or melphalan in 83 cell lines revealed substantial activity in MM and diffuse large B cell lymphoma cell lines.
- In some of the multiple myeloma (MM) cell line models, A2A and beta-2 adrenergic receptor agonists synergized with melphalan, lenalidomide, bortezomib and doxorubicin.
- Combination effects were also observed with dexamethasone as well as bortezomib, using MM patient samples and mouse MM xenograft assays.
- Results support development of A2A and beta-2 adrenergic receptor agonists for use in multi-drug combination therapy for MM.
- Systematic combination screening for the discovery and evaluation of new targets and combination therapies has the potential to improve cancer treatment paradigms and patient outcomes.
Zalicus Discovers Novel Multi-Target Mechanism For The Treatment Of Multiple Myeloma
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.